Clinical Trials
68 trialsStudy BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
ADVANCED-2
Protara Therapeutics
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
BAYOU
AstraZeneca
SunRISe-1
Janssen Research & Development, LLC
panSOHO
Bayer
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
EMD Serono
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
CG Oncology, Inc.
INTerpath-011
Merck Sharp & Dohme LLC
exBOND
CG Oncology, Inc.
SunRISe-4
Janssen Research & Development, LLC
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
CatalYm GmbH
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Merck Sharp & Dohme LLC
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
PRESERVE3
G1 Therapeutics, Inc.
KEYVIBE-005
Merck Sharp & Dohme LLC
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
EMD Serono
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
EV-201
Astellas Pharma Inc
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
CicloMed LLC
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
Hoffmann-La Roche
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
Hoffmann-La Roche
LODESTAR
pharmaand GmbH
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Endocyte
ATLAS
pharmaand GmbH
CheckMate 9UT
Bristol-Myers Squibb
PIVOT-10
Nektar Therapeutics
MK-3475-052
Merck Sharp & Dohme LLC
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Infinity Pharmaceuticals, Inc.
OPTIMA II
UroGen Pharma Ltd.
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bavarian Nordic
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
STCC
Cadila Pharnmaceuticals
BOND2
CG Oncology, Inc.
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Taizhou Hanzhong biomedical co. LTD
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Dragonboat Biopharmaceutical Company Limited
ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.
Fidia Farmaceutici s.p.a.
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
Sesen Bio, Inc.
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Celldex Therapeutics
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
KAMELEON
Hoffmann-La Roche
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Biofabri, S.L